bortezomib 
takeda
['mds', 'aml,(-streamline),(-seamless),(-kamloops)', 'mmsm']
 no diff in secondary primary malignancies, however 0 aml/mds in rvd alone vs 10 in asct groups (p=0.002) lastly, no sig diff in os, with only 11.8% &amp; 21.4% patients in rvd alone or asct cohorts respectively receiving cd38-directed therapy in subsequent line
#asco22 #mmsm
Myeloma Clinical Investigator @DanaFarber @harvardmed via @MoffittNews USF Heme/onc, @NorthwesternU BME, Baker, Jersey girl. Views = my own, not employer